“A Registry of Patients With Moderate to Severe Plaque Psoriasis”
The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis.
Drug - Secikinumab
A Registry of Patients With Moderate to Severe Chronic Plaque Psoriasis in Canada and Latin AmErica (LACan)
NCT02786186
QeZGQa